BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that five abstracts from clinical and in-vitro
studies of ITMN-191 (R7227) and the company's research programs related to the
hepatitis C virus (HCV) have been accepted for presentation at the 44th Annual
Meeting of the European Association for the Study of the Liver (EASL, April
22-26, 2009 in Copenhagen, Denmark). The abstracts are expected to be
available at www.easl.ch. ITMN-191 is an HCV NS3 protease inhibitor, being
developed in collaboration with Roche.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune,
said, "Collectively, these abstracts demonstrate that ITMN-191 is a promising,
potent antiviral compound for the treatment of HCV and underscore our
company's continued progress in the research of new compounds for HCV
Presentations of ITMN-191 Clinical Results
-- Antiviral Activity and Safety of ITMN-191 in Combination with
Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis
C Virus (HCV).
-- Incidence of Virologic Escape Observed During ITMN-191 Monotherapy is
Genotype Dependent, Associated with a Specific NS3 Substitution, and
Suppressed Upon Combination with Peginterferon alfa-2a/Ribavirin.
Additional InterMune Presentations at EASL
Titles of additional InterMune posters to be presented at EASL are as
-- Combination of the NS3/4A Protease Inhibitor ITMN-191 with the
Allosteric NS5B Polymerase Inhibitor ITMN-8020 Enhances Replicon
Clearance and Reduces the Emergence of Drug Resistant Variants.
-- Discovery of Potent, Bioavailable HCV NS3/4A Inhibitors that Display
Unimpaired Activity Against an NS3 Sequence Variant Associated with
Resistance to Linear Tetrapeptides and Macrocyclic Inhibitors.
-- A Mouse Model with Long Term Expression of Hepatitis C Virus NS3/4A
Protease for the Pharmacokinetic and Pharmacodynamic (PK-PD) Study of
HCV Protease Inhibitors
The European Association for the Study of the Liver (EASL) is the leading
European association in the field of liver research. EASL brings together
clinicians and scientists interested in the liver, providing an outlet for
networking and learning. The EASL Annual Meeting attracts more than 7,000
InterMune is a biotechnology company focused on the research, development
and commercialization of innovative therapies in pulmonology and hepatology.
InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis
(IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio
includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a
possible therapeutic candidate for the treatment of patients with IPF and a
research program focused on pirfenidone analog ITMN-520. The hepatology
portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to
as R7227 at Roche) expected to enter Phase 2b in the summer of 2009, a
second-generation HCV protease inhibitor research program, and a research
program evaluating a new target in hepatology. For additional information
about InterMune and its R&D pipeline, please visit www.intermune.com.
This news release contains forward-looking statements within the meaning
of section 21E of the Securities Exchange Act of 1934, as amended, that
reflect InterMune's judgment and involve risks and uncertainties as of the
date of this release, including without limitation the statements related to
anticipated product development timelines. All forward-looking statements and
other information included in this press release are based on information
available to InterMune as of the date hereof, and InterMune assumes no
obligation to update any such forward-looking statements or information.
InterMune's actual results could differ materially from those described in
InterMune's forward-looking statements.
Factors that could cause or contribute to such differences include, but
are not limited to, those discussed in detail under the heading "Risk Factors"
in InterMune's most recent annual report on Form 10-K filed with the SEC on
March 16, 2009 (the "Form 10-K") and other periodic reports filed with the
SEC, including the following: (i) risks related to the long, expensive and
uncertain clinical development and regulatory process, including having no
unexpected safety, toxicology, clinical or other issues or delays in
anticipated timing of the regulatory approval process; (ii) risks related to
failure to achieve the clinical trial results required to commercialize our
product candidates; and (iii) risks related to timely patient enrollment and
retention in clinical trials. The risks and other factors discussed above
should be considered only in connection with the fully discussed risks and
other factors discussed in detail in the Form 10-K and InterMune's other
periodic reports filed with the SEC, all of which are available via
InterMune's web site at www.intermune.com.
SOURCE InterMune, Inc.
Jim Goff of InterMune, Inc.,
Web Site: http://www.intermune.com